Anchor-Protein Cell-Derived Vesicles for Stable Drug Loading
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing drug delivery systems face challenges with high cytotoxicity, complex processes, and low intracellular delivery efficiency, limiting their suitability for clinical applications, particularly for delivering biologically active molecules like nucleic acids and proteins.
Innovation Solution
Engineered cell-derived vesicles (CDVs) overexpressing anchor proteins, such as Basigin, ATP1B3, LAMP1, and LAMP2, which facilitate stable loading and targeted delivery of biologically active molecules, including therapeutic drugs and targeting ligands.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If natural extracellular vesicles are used for drug delivery, then biocompatibility and intercellular signaling functions are improved, but collection and concentration require considerable effort with limited quantity
Solution Approach 1:
The patent creates artificial cell-derived vesicles (CDVs) that copy the essential features of natural extracellular vesicles (biocompatibility, membrane structure, intercellular signaling) while using a mass production approach. The CDVs are generated through a standardized protocol involving cell transfection with plasmids encoding target proteins, followed by mechanical extrusion, enabling large-scale production while maintaining the beneficial properties of natural EVs.
Solution Approach 2:
The patent modifies key parameters of vesicle production by using a controlled cell culture system with specific plasmid transfections and standardized mechanical extrusion parameters. This allows precise control over vesicle composition, size, and quantity, transforming the uncontrolled natural secretion process into a reproducible manufacturing process that yields high quantities of uniform vesicles.
2Productivity
If cationic polymers and liposomes are used as drug carriers, then drug delivery capability is improved, but cytotoxicity becomes too high for clinical application
Solution Approach 1:
The patent employs cell-derived vesicles as a biocompatible alternative to synthetic carriers like cationic polymers and liposomes. These CDVs utilize the natural membrane components of host cells (which can be easily replaced) to create a non-toxic delivery platform that maintains drug delivery efficiency while eliminating the cytotoxicity associated with conventional synthetic carriers.
Solution Approach 2:
The patent creates composite vesicle structures by incorporating target proteins into the CDV membrane through plasmid transfection. This composite approach combines the biocompatible lipid bilayer of natural vesicles with engineered protein components that provide targeting functionality, achieving both safety and functional efficacy without the cytotoxicity of purely synthetic carriers.
3Adaptability or versatility
If nanoparticle-based systems such as graphene quantum dots and magnetic particles are used, then various materials can be delivered, but cytotoxicity increases and intracellular delivery efficiency decreases
Solution Approach 1:
The patent uses cell-derived vesicles as intermediary carriers that naturally interact with cell membranes through their lipid bilayer structure. This intermediary approach avoids the direct cytotoxic interaction between inorganic nanoparticles and cell membranes, while still enabling efficient intracellular delivery through mechanisms that leverage the natural endocytic pathways of the host cells.
Solution Approach 2:
The patent replaces the mechanical penetration mechanisms required for inorganic nanoparticle entry with a biochemical approach utilizing the natural membrane fusion and endocytic processes of cell-derived vesicles. This substitution eliminates the need for forceful membrane penetration that causes cytotoxicity while maintaining effective intracellular delivery through physiological mechanisms.
4Stability of the object's composition
If chemical modification of nucleic acid molecules is performed to enable direct passage through cell membranes, then delivery stability is improved, but the process consumes a lot of time and money with complex procedures
Solution Approach 1:
The patent segments the delivery system into two functional components: (1) the cell-derived vesicle carrier that provides membrane penetration capability through its natural lipid bilayer structure, and (2) the nucleic acid payload that remains chemically unmodified. This segmentation eliminates the need for complex chemical modification of nucleic acids while achieving stable membrane penetration through the vesicle's inherent properties.
Solution Approach 2:
The cell-derived vesicle acts as an intermediary that bridges the gap between extracellular space and intracellular compartments. Instead of chemically modifying nucleic acids to directly penetrate membranes, the vesicle serves as a pre-formed intermediary structure that naturally facilitates the transport of encapsulated materials through the membrane barrier, simplifying the overall process.
Data Source
AI summary
The present invention relates to engineered cell-derived vesicles (CDVs) that can be used as a drug delivery system, and was completed by discovering four types of anchor proteins that match the intrinsic characteristics of CDVs and can mediate the stable introduction of biologically active molecules. The anchor proteins are CDV-specific membrane proteins that are abundantly present, and it was confirmed that CDVs comprising the anchor proteins can be more stably loaded with biologically active molecules. For example, as a result of carrying out comparative experiments by using a fluorescent protein, it was confirmed that CDVs into which the anchor proteins are introduced were more effectively loaded with the fluorescent protein, compared to CDVs without the anchor proteins. It was also confirmed that, when a cancer cell-targeting antibody was loaded into the engineered CDVs of the present invention, the engineered CDVs exhibited an increased ability to target cancer cells and were more effectively absorbed into cancer cells. That is, the CDVs of the present disclosure are BioDrone engineered with the anchor proteins and can be stably loaded with various biologically active molecules and deliver same to a target of interest, and thus are expected to be used as a platform for the delivery of various drugs and treatment.